Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia
News | 09. 16. 2019
SAN DIEGO, Sept. 16, 2019 — Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that two independent review committees completed their planned safety and efficacy assessment of data from 50% of the planned study population enrolled in the Company’s Phase 2 open-label clinical trial of fosmanogepix (APX001) for the treatment of candidemia.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.